Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1.0 billion aggregate principal amount of new senior secured notes due 2027 (the "Notes"). As previously announced, the Company is also seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur upon completion of the initial public offering ("IPO") of Bausch + Lomb Corporation ("Bausch + Lomb" and such offering, the "Bausch + Lomb IPO") and a related debt financing by Bausch + Lomb (the "Bausch + Lomb Debt Financing").

Read More
NewsCatherine LamontagneBauschhealth, Bausch
Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update
Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update

Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder complications. Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation, and the Company will actively pursue the advancement of INV-202 into later-stage clinical trials.

Read More
NewsCatherine LamontagneInversago Pharma, clinical trials
Carebook and LifeLabs Working Together to Deliver Personalized, Digital Healthcare Insights
Carebook and LifeLabs Working Together to Deliver Personalized, Digital Healthcare Insights

Carebook Technologies Inc. ("Carebook" or the "Company") (TSXV: CRBK) (OTCPK: CRBKF) (XETR: PMM1), a leading Canadian provider of innovative digital health solutions, announced today that they will be working with LifeLabs, Canada's largest community medical laboratory network, to deliver valuable insights to LifeLabs' MyCareCompass customers through integration with Carebook's CoreHealth Assessment Tool. This multi-year licensing agreement will deliver even greater value to LifeLabs' customers, empowering them to conveniently manage their healthcare through MyCareCompass.

Read More
NewsCatherine LamontagneCarebook, LifeLabs, Digital Healthcare
Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron
Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron

Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron variant. IBIO123 is an inhaled antibody-based immunotherapy with an ongoing multisite phase 1 and 2 clinical program for the treatment of symptomatic SARS-CoV-2 patients.

Read More
NewsCatherine LamontagneImmune Biosolutions, COVID-19, Omicron
Valence Discovery Announces $8.5 Million in Seed Funding to Scale AI-Based Generative Chemistry Engine and Collaborations with Leading Discovery Organizations
Valence Discovery Announces $8.5 Million in Seed Funding to Scale AI-Based Generative Chemistry Engine and Collaborations with Leading Discovery Organizations

Valence Discovery, a leader in AI-first design of novel chemistry against previously intractable biology, announced today that it has closed an oversubscribed US$7 million seed financing. The financing, which was co-led by Fifty Years and Air Street Capital, with participation from Amplitude Ventures, Phoenix Venture Partners, and Abcam founder and former CEO, Jonathan Milner, adds to US$1.5 million raised previously, bringing Valence’s total seed funding to US$8.5 million. The new funds will support expanding Valence’s AI-based generative chemistry engine, scaling its partnerships with world-class discovery organizations, further building a leading team of interdisciplinary scientists, and advancing internal drug discovery efforts.

Read More
NewsGuest UserValence Discovery, AI
Laurent Pharmaceuticals Extends COVID-19 Phase 2 Study with Oral Antiviral LAU-7b that has Showed 100% Reduction in the Risk of Progression onto Mechanical Ventilation and Death
Laurent Pharmaceuticals Extends COVID-19 Phase 2 Study with Oral Antiviral LAU-7b that has Showed 100% Reduction in the Risk of Progression onto Mechanical Ventilation and Death

MONTREAL--(BUSINESS WIRE)--Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed the Phase 2 RESOLUTION study extension in hospitalized moderate-to-severe adult COVID-19 patients and the change of the primary endpoint to “proportion of patients requiring mechanical ventilation and/or death by Day 60.” The company also announced that the FDA has granted a Type B meeting request to discuss, among other topics, the eligibility to Emergency Use Authorization (EUA) and Phase 3 clinical trials with LAU-7b in COVID-19, in both hospitalized and ambulatory settings. The meeting will take place on January 14th, 2022, via conference call.

Read More
NewsGuest UserLaurent Pharmaceuticals, COVID-19
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

LAVAL, Quebec--(BUSINESS WIRE)--Dec. 13, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ≤ 0.005) at day 28. BLU-5937 was generally well-tolerated, with low rates of taste-related adverse events reported (≤6.5%) at all doses.

Read More
NewsCatherine LamontagneBellus Health, clinical trials
CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation
CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation

During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection of lung cancer. Funding for this collaborative research project is made possible with the financial support of the ministère de l’Économie et de l’Innovation (MEI) who will be providing $1.36M as part of CQDM’s SynergiQC program.

Read More
NewsCatherine LamontagneCQDM, Biomark, Pfizer, Astrazeneca
Angany Announces Vaccine Candidate to Treat Peanut Allergy
Angany Announces Vaccine Candidate to Treat Peanut Allergy

Angany Inc., announces today that it has entered into a partnering agreement with Dr. Wayne Shreffler, MD, PhD, Chief, Division of Pediatric Allergy & Immunology and Director of the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children, for a comprehensive series of preclinical studies of Angany’s peanut allergy biologic candidate BP/AH-01.

Read More
NewsGuest UserAngany, vaccine, Peanut Allergy
Appointment of Luc Paquet as Chief Executive Officer - Immune Biosolutions enters into a new chapter of its growth
Appointment of Luc Paquet as Chief Executive Officer - Immune Biosolutions enters into a new chapter of its growth

Immune Biosolutions Inc. is consolidating its biopharmaceutical transition, following the accelerated development of its activities. The company will focus its activities towards the discovery and development of immunotherapies for infectious diseases, inflammation and cancer. To propel Immune Biosolutions' growth in this new phase, the company is pleased to announce the appointment of Mr. Luc Paquet as Chief Executive Officer.

Read More
NewsCatherine LamontagneImmune Biosolutions
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), for the treatment of patients with relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).

Read More
NewsGuest UserIncyte